Tactogen is developing ‘a next generation of medicines for mental health’ under the leadership of Matthew Baggott.
Tactogen
The company has not made any concrete announcements. On their LinkedIn page it can be found that they are working on empathogen medicines (MDMA is often classified as such).
In April 2021, Tactogen raised U$1.5 million through early-stage venture capital.
The company has indicated that it’s a public benefit corporation.
“We are a public benefit corporation. We seek to improve and sustain individual and community health, primarily by developing safe, effective, and accessible medicines.”
Activities
B2C
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.